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Endotoxin and nanobacteria in polycystic kidney disease. and microbe may have added importance and nuance
Background. Microbes have been suspected as provocateurs in diseases once viewed as being exclusively caused by
of polycystic kidney disease (PKD), but attempts to isolate viable genetic anomalies. In such cases, an understanding oforganisms have failed. Bacterial endotoxin is the most often
both the human genetic mutation and resultant biologyreported microbial product found in PKD fluids. We assessed
must be matched with the relevant human microbe(s)potential microbial origins of endotoxin in cyst fluids from 13
PKD patients and urines of PKD and control individuals. to fully understand the disease process and potential
Methods. Fluids were probed for endotoxin and nanobac- therapies.
teria, a new bacterium, by the differential Limulus Amebocyte Environmental factors are reported to influence theLysate assay (dLAL), genus-specific antilipopolysaccharide
progression of polycystic kidney disease (PKD), the most(LPS) antibodies, monoclonal antibodies to nanobacteria, and
prevalent autosomal dominant disease in humans [2–6].hyperimmune serum to Bartonella henselae (HS-Bh). Selected
specimens were also assessed by transmission electron micros- In addition to the inherited mutated PKD allele, autoso-
copy (TEM) and nanobacterial culture methods. mal dominant PKD (ADPKD) offspring may themselves
Results. LPS or its antigenic metabolites were found in more
undergo multiple focal, intrarenal mutations of the re-than 75% of cyst fluids tested. Nanobacteria were cultured
maining normal PKD allele (that is, loss of heterozygos-from 11 of 13 PKD kidneys, visualized in 8 of 8 kidneys by
TEM, and immunodetected in all 13 PKD kidneys. By immuno- ity), resulting in rapid expansion of cysts via clonal
detection, nanobacterial antigens were found in urine from 7 growth of the “double-hit” cells [7, 8]. Damage or muta-
of 7 PKD males, 1 of 7 PKD females, 3 of 10 normal males, tion of the remaining normal PKD allele has been specu-
and 1 of 10 normal females. “Nanobacterium sanguineum” was
lated to involve local metabolic stresses, misalignmentdLAL positive and cross-reactive with antichlamydial LPS and
of vulnerable DNA structures, and the actions of mi-HS-Bh. Some cyst fluids were also positive for LPS antigens
from Escherichia coli, Bacteroides fragilis and/or Chlamydia, crobes and their toxins [9–11]. In some experimental
and HS-Bh, as were liver cyst fluids from one patient. Tetracy- forms of PKD, germ-free conditions protect against cys-
cline and citrate inhibited nanobacterial growth in vitro. togenesis, but the addition of bacterial endotoxin pro-Conclusion. Nanobacteria or its antigens were present in
vokes cystogenesis [3–5]. The greater incidence of infec-PKD kidney, liver, and urine. The identification of candidate
tions and resultant greater morbidity and mortality inmicrobial pathogens is the first step in ascertaining their contri-
bution, if any, to human disease. PKD individuals than the general population have
prompted speculation that PKD may involve an as yet
uncharacterized defect in microbe clearance mechanisms
New technologies are verifying the old idea that mi- [12–14]. In addition, the approximately 80% of PKD
crobes or their parts cause chronic disease in humans, patients reported to have colonic anomalies described as
in whom both the genetic background of the patient and diverticula may show greater bioavailability of microbial
microbe(s) interact to influence disease initiation and/or products derived from the diet and microflora, as ob-
progression [1]. Such interactions of genetic background served in “leaky gut syndrome” [6, 15, 16].
Although interstitial renal inflammation occurs in
PKD, it is not known whether this inflammation is dueKey words: Chlamydia, Bartonella, Bacteroides, liver cysts, simple cys-
tic disease, tetracycline, citrate. exclusively to PKD cell biology or microbial factors im-
pacting kidney and other affected tissues, especially theReceived for publication July 13, 1999
gastrointestinal and cardiovascular systems. Bacterialand in revised form September 21, 1999
Accepted for publication January 3, 2000 endotoxin [lipopolysaccharide (LPS)], a potent nephro-
toxic inflammatory substance, has been found in PKDÓ 2000 by the International Society of Nephrology
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cyst fluid and urine [9, 17, 18]. LPS is composed of a uals previously reported for endotoxin content was also
analyzed for nanobacterial antigens [17].lipid A moiety, core polysaccharides, and O-antigens.
Antibodies to the core polysaccharides of genus-specific Endotoxin in cyst fluids and urine was assayed by
dLAL using the gel clot endpoint as previously describedLPS have been used to detect microbes in tissue and
fluids and provide insight into pathophysiologic mecha- (Charles River ENDOSAFE, Charleston, SC, USA) [9].
Each specimen was assayed in duplicate with serial dilu-nisms. In this study of endotoxin in PKD, we used genus-
specific LPS antibodies to ascertain the microbial origins tions to assess the concentration. To expose epitopes in
a few select experiments, nanobacteria were demineral-of endotoxin present in human PKD cyst fluids.
In the course of this work, in PKD serum, cyst fluids, ized by incubation in 100 mmol/L EGTA made in sterile,
pyrogen-free water for one hour at 378C. Following de-and urine we found evidence of nanobacteria, a recently
discovered, novel, calcium apatite-forming bacterium mineralization, both the 15,000 3 g pellet and supernate
were amenable to dLAL and dot immunoblot assay;that is undetectable by routine microbiological culture
methods [19–22]. Nanobacteria exhibit an array of effects such concentrations of EGTA in the specimen did not
interfere with these assays.in animals and in vitro culture that are plausibly related
to the known anomalies of PKD. For example, intrave- For the detection of LPS antigens, lyophilized cyst
fluids reconstituted in commercial pyrogen-free water tonously injected nanobacteria are renotropic and cause
apoptosis of kidney tubule cells and sloughing of renal one tenth of their original volume were dot blotted (2 mL)
onto nitrocellulose paper, blocked with 3% gelatin, indi-tubule cells into the urine, and they are found in 97%
of kidney stones [23–27]. Nanobacteria cause mineraliza- vidually exposed to genus specific anti-LPS antibody pre-
pared in mouse or rabbit, washed, probed with a horse-tion in vitro under physiological concentrations of cal-
cium and phosphate [20, 21, 24, 25]. Dysregulation of radish peroxidase (HRP)-linked antimouse or antirabbit
IgG secondary antibody, washed, and reacted with HRP-apoptosis and tubular obstruction is reported in PKD,
as is a heightened occurrence of kidney calcification amplifying reagents to give a purple color [33]. Negative
controls included pyrogen-free water as specimen; PKD[28–31]. Awareness that viable nanobacteria are present
and control specimens were processed as experimental,in human PKD kidney is important for future tests of
except that incubation with the primary antibody wasenvironmental factors that impact the genetically unique
omitted. Positive controls used genus-specific LPS asaspects of PKD biology as well as broader issues of the
the test specimens. The intensity of HRP reaction wasrole of nanobacteria in health and disease.
visually estimated and rated from 0 to 5, the greatest
intensity. Monoclonal antibodies (mAbs) against “Nano-
METHODS bacterium sanguineum” antigens were used separately
Kidneys from 13 patients with ADPKD were obtained as the primary antibody in the dot immunoblot assays
in cold University of Wisconsin solution [32] within two described earlier in this article. [Note: “Nanobacterium
hours of nephrectomy at UICOM-Department of Sur- sanguineum” is the type culture designate for nanobac-
gery, St. Francis Medical Center (Peoria, IL, USA). Han- teria. It has been deposited in the German Collection of
dling of the kidneys and aspirated cyst fluids was done Microorganisms (DSMZ no. 5819; Braunschweig, Ger-
using aseptic techniques, tools rendered pyrogen- and many) and is described in U.S. patent no. 5,135,851,1992.
glucan-free by heating at 1608C for four hours, and pyro- The 16S rRNA gene sequence is available in GENBANK
gen- and fungal glucan-free reagents, as determined by (accession No. X98418). “N. sanguineum” was isolated
differential Limulus Amebocyte Lysate assay (dLAL) from bovine serum and is the source of antigens used in
[9]. The dLAL distinguished endotoxin from fungal glu- the preparation of mAbs.] Dot-immunoblot assays used
cans. Cyst fluids were individually aspirated, cultured by the following antibodies [34]: Enteric mAb WN1222.5
routine microbiological methods, and stored at 2608C for rough/smooth LPS of Escherichia coli, Salmonella,
for later analysis of endotoxin content, immunodetec- Shigella; Bacteroides “C” (common LPS antigen) poly-
tion, transmission electron microscopy (TEM), and na- clonal antiserum; mAb B7 to Chlamydia spp. LPS; mAb
nobacteria culture, as described later in this article. In Nb 8/0 (porin protein epitope) and Nb 5/2 (carbohydrate
one PKD patient (donor 2; Table 1), liver cyst fluids peptidoglycan epitope) of nanobacteria [24]; and hyper-
were individually aspirated prior to nephrectomy. In a immune antisera to Bartonella henselae from infected
patient with simple renal cysts (donor 13), 200 mL of mice (gift of K. Karem) [35]. The antibody to Bacteroides-
fluid from a single cyst were obtained by radiologically LPS used in this study reacted with LPS purified from
guided needle aspiration under local anesthetic. Blood Bacteroides fragilis, the predominant species associated
by venipuncture and midstream, clean catch urine were with the colonic mucosa [36]; however, the antibody did
obtained from a 23-year-old PKD Finnish male with not react with LPS of B. vulgatus, the predominant spe-
rapidly enlarging renal cysts but normal creatinine and cies in the colonic lumen and feces. The dot-immunoblot
and immunofluorescence (IF) procedures were used tourea levels. Urine from PKD and healthy control individ-
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Table 1. Findings of endotoxin and nanobacteria by several methods in kidney and liver samples from patients with cystic kidney disease
Endotoxin by dot immunoblot (IB) Nanobacteria by dot immunoblot,
Endotoxin (No. positive/tested; IB score)c electron microscopy, and culture (p/t)c,d
Donor no. by dLALb
Patient dataa p/t;EU/mL E.coli B. fragilis Chlamydia Nb 8/0 Nb 5/2 EM Culture
(1) AD 46y/F HD 2/9;0.51 7/9;3.4 3/9;2.0 7/9;2.3 2/3;3.5 2/3;4.0 Yes 1/2
(2) AD 56y/F T 4/21;0.11 6/21;2.7 4/21;2.3 12/21;3.6 6/6;2.3 5/6;1.7 Yes 2/2
and Liver CF 1/10;0.04 10/10;3.3 2/10;3.0 10/10;3.7 10/10;3.9 10/10;3.2 0/1
(3) AD 38y/M HD 3/23;0.38 13/22;3.4 7/22;3.0 12/22;2.9 9/9;2.8 9/9;2.7 Yes 2/2
(4) AD 60y/M T 3/20;0.19 17/22;3.6 5/22;2.6 16/22;2.9 8/8;2.9 8/8;2.6 0/2
(5) AD 47y/F T 2/14;0.12 12/16;3.1 3/16;1.3 10/16;2.8 4/6;2.5 5/6;2.0 Yes 2/2
(6) AD 47y/F HD 3/11;0.20 4/4;2.0 0/4;0.0 1/4;3.0 3/6;2.3 3/6;2.7 0/1
(7) AD 43y/F PD 4/13;0.21 8/8;3.1 5/8;1.3 6/9;3.7 7/7;3.3 7/7;1.7 Yes 2/2
(8) AD 37y/M 2/11;3.84 6/6;3.0 4/6;2.0 2/6;2.0 3/4;4.0 3/4;2.3 Yes 2/2
(9) AD 41y/F 3/16;0.88 9/9;2.2 4/8;1.7 6/9;2.4 2/4;2.5 2/4;1.5 1/1
(10) AD 52y/F 4/6;1.71 6/6;3.3 1/6;4.0 3/5;2.3 3/4;2.5 3/4;3.0 2/2
(11) AD 45y/F 3/5;0.48 5/6;3.6 4/6;2.5 6/6;2.5 3/3;2.7 3/3;3.7 2/2
(12) AD 48y/M 11/20;1.60 8/8;3.4 6/8;2.3 9/9;2.9 4/4;2.5 4/4;3.5 Yes 1/1
(13) SC 48y/F 200 mL;3.84 4.0 2.0 3.0 4.0 4.0 Yes Yes
(14) AD 40y/F HD T 9/11;3.6 Yes 15/15
aAD, autosomal dominant PKD; SC, simple cyst fluid; age in y(ears)/F(emale), M(ale); HD, hemodialysis; T, transplanted; PD, peritoneal dialysis; Liver CF, cyst
fluid
bdLAL, differential Limulus Amebocyte Lysate assay; p/t, positive finding/per number of cyst fluids tested; EU/mL, endotoxin units per mL (1 EU 5 ,0.1 ng of
standard E. coli LPS). Blank cells indicate not tested.
cDot-immunoblot assays used the following Abs: Enteric mAb WN1 222.5 for rough/smooth LPS of E. coli, Salmonella, Shigella; Bacteroides “C” (common LPS
antigen) polyclonal antiserum; mAb B7 to Chlamydia spp. LPS; mAb Nb 8/0 (porin protein epitope) and Nb 5/2 (carbohydrate peptidoglycan epitope) of Nanobacterium.
A visual scoring scheme rated the intensity of the immunoreactions from 0 to 5, the highest positivity. Positive reaction scores were averaged.
dEM, transmission electron microscopy: Yes indicates the presence of structures (Figs. 1 and 2) compatible with type species designate, “Nanobacterium sanguineum.”
assess any cross-reactivity of primary antibodies between For ADPKD patient 14, cyst fluids were collected as
mentioned previously in this article, but were culturedthe various LPSs and “N. sanguineum” [19]. Negative
control was assayed without primary antibody. within two hours of nephrectomy. Aliquots (0.5 mL) of
nonfiltered and filtered (0.45 m pore size; Millipore Corp.,Dissected kidney tissue and pellets of cyst fluids
(15,000 3 g, 45 min) were prepared for electron micros- Bedford, MA, USA) cyst fluid were placed in 5 mL
of RPMI-1640 (Cellgro Mediatech Inc., Herndon, VA,copy by initial fixation in cold 2.5% glutaraldehyde and
processing as previously described [37]. For nanobact- USA) with and without 10% Hg-FBS (Life Technolo-
eria, uranyl acetate staining was omitted without loss or gies, Grand Island, NY, USA) in T-25 flasks and incu-
alteration of nanobacterial morphology. bated as previously in this article. After one month, the
For culture of nanobacteria (donors 1 through 13), cultured cyst fluids were examined by phase light and
frozen original cyst fluids or urines were thawed; 0.5 mL electron microscopy. Sterile controls were media with
aliquots of the original and filtered (0.22 m pore size and without Hg-irradiated serum.
filter) were placed in 5 mL of RPMI-1640 with l-gluta- An initial determination of cytotoxic potential of na-
mine (GIBCO, Paisley, Scotland, UK) supplemented nobacteria from PKD patients used a 3T6-fibroblast
with 10% high g-irradiated (30 kGy), heat-inactivated (ATCC CCL 96) test system described elsewhere [26].
fetal bovine serum (Hg-FBS; Atlanta Biologicals, At- The loss of fibroblasts caused by cell lysis was easily
lanta, GA, USA) in T-25 tissue culture flasks and incu- observed by direct microscopic inspection.
bated at 378C in a humidified 5% CO2/95% air environ- Nanobacterial growth in response to tetracycline and
ment for three weeks [19–21, 26]. The identification of citrate solutions was assessed in 96-well plates by re-
nanobacteria used phase contrast microscopy, IF assay cording the increase in optical density at 650 nm over a
with Nb 8/0 as the primary antibody, differential DNA- 14-day period [22, 25]. Serial dilutions of potassium ci-
staining using Hoechst 33258 fluorochrome (Flow Labo- trate-citric acid solution described by Tanner were made
ratories, Ayrshire, Scotland, UK) that distinguishes na- in Dulbecco’s modified Eagle’s medium with 1 mmol/L
nobacteria from common bacteria, and a double staining glutamine (DMEM; Sigma, St. Louis, MO, USA) [38].
method that combined both IF and Hoechst methods
[19, 20, 23, 24, 26]. The results were recorded by light
RESULTSand fluorescence photomicroscopy. TEM was also used
Endotoxin or its remnants were found in all PKDto visualize nanobacteria in specimens with the type cul-
kidneys examined in this study. Table 1 lists our findingsture designate serving as the control for growth and
morphologic comparison. of endotoxin by dLAL and dot-immunoblot method.
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For each patient, the number of cyst fluids found to be these data do not exclude the possibility that chlamydial
LPS is also present. The lack of strict stoichiometrypositive by dLAL for endotoxin per the number of fluids
tested (p/t) is given. For the dLAL assay, the average across microbial epitopes may reflect different rates of
generation, release, and degradation within cyst fluid orlevel of detected endotoxin expressed in endotoxin units
(EUs)/mL cyst fluid is given for those cysts positive for delivery of epitopes to cysts from other sites.
By dot-immunoblot assay, 10 of 10 liver cyst fluidsendotoxin. In patients 1 through 7, all of whom had been
on dialysis or received a kidney transplant prior to ne- positive for nanobacteria were also positive for Barto-
nella (donor 2; Table 1). In 31 kidney cyst fluids selectedphrectomy, the average endotoxin load (0.245 EU/mL)
was sevenfold lower than for patients 8 through 12 (1.70 from the ADPKD donors 1 through 12, a very similar
but not identical distribution of antigens for these organ-EU/mL) who had not received renal replacement ther-
apy. The incidence of dLAL positivity for cyst fluids isms was observed. Twenty-one fluids were positive for
both Bartonella and nanobacteria (Nb 8/0 and 5/2). Sevenwithin each kidney was also lower in the renal replace-
ment group (20.2 vs. 43.7%, respectively). were negative for both organisms. One was weakly posi-
tive only for nanobacteria (Nb 8/0 and 5/2), and twoIn ADPKD patients, there was a greater rate of positi-
vity by dot-immunoblot for endotoxin than by dLAL were weakly positive only for Bartonella. Washed, intact
nanobacteria were negative by dot-immunoblot assay to(Table 1). The LPS antibodies recognized epitopes in
the core polysaccharides of LPS and thus did not require hyperimmune serum to B. henselae (HS-Bh). However,
incubation of nanobacteria at 378C for one hour in 100an intact lipid A moiety for reactivity. A difference in
the rates of dLAL and dot immunoblot positivity sug- mmol/L EGTA rendered the decalcified nanobacteria
reactive with HS-Bh; no reaction was observed whengests the presence of LPS remnants, which was observed
in all PKD kidneys examined in this study. HS-Bh was omitted from the assay. Simple kidney cyst
fluid from donor 13 also reacted with these antibodies“Nanobacterium sanguineum” was positive for endo-
toxin, but not glucan by the dLAL assay; pretreatment (Table 1). HS-Bh did not react with ATCC reference
strains of E. coli or B. fragilis.of “N. sanguineum” and nanobacteria from donor 14
with EGTA prior to dLAL assay enhanced endotoxin In an earlier study, we found endotoxin in the urine
of a majority of PKD patients, but only comparativelypositivity eightfold. By TEM, PKD kidney tissue and
cyst fluids exhibited mineralized structures compatible low levels in control females and none in control males
[17]. Here, we assayed archived urine from the previouswith nanobacteria (Figs. 1 and 2); neither Chlamydia nor
Bartonella-like structures nor other common microbes study by dot-immunoblot using Nb 8/0 and WN1 222.5
(Table 2). Nb 8/0 gave the highest positivity in PKDwere observed. Antibodies Nb 8/0 and Nb 5/2 against
“Nanobacterium sanguineum” showed a high incidence males with normal males showing greater positivity than
normal females. In one PKD male, four sequential urineof positivity in kidney cysts from all 13 ADPKD patients
(Table 1) [19, 23]. Positivity was also observed in liver samples collected over a two year period exhibited Nb8/0
positivity (scores 3, 1, 2, 4), while three urines from eachcyst fluids and simple kidney cyst fluid where available.
As exemplified by Figure 1H, common bacteria were of two PKD females remained negative over this same
period. The antibodies against E. coli LPS was reactivenot present, as determined by Hoechst staining, in the
nanobacteria cultures from PKD cyst fluids. with all PKD male urines; 4 of 10 of the normal females
were also WN1 222.5 positive.During checks of antibody specificity, chlamydial LPS
mAb was observed to react with washed, intact nano- Structures consistent with nanobacteria were observed
by TEM in PKD kidney tissue (Table 1 and Fig. 1).bacteria. This mAb did not cross-react with purified LPS
from either E. coli (ATCC #25922) or B. fragilis (ATCC Nanobacteria were cultured from frozen kidney cyst flu-
ids from donors 1, 2, 3, 5, 7 through 13 and identified#25215), reference organisms used by the National Com-
mittee for Clinical Laboratory Standards. “Nanobacter- by IF methods (Table 1 and Fig. 1). They were also
found by culture and IF in blood and urine samples fromium sanguineum” did not react with the other LPS anti-
bodies. This raised the possibility that our positive a 23-year-old Finnish male PKD patient. Multiple kidney
cyst fluids were cultured without prior freezing fromfindings of chlamydial LPS in cyst fluids could be due to
the LPS of nanobacteria. donor 14 (Table 1), who had received both hemodialysis
for 10 months and a kidney transplant 4 months priorOf the 66 kidney and liver cyst fluids assayed using
mAb to chlamydia LPS and nanobacterial porin and to nephrectomy. All 15 nonfiltered cyst fluids grown in
serum for four weeks were nanobacteria positive by lightpeptidoglycan antigens (Nb 8/0 and Nb 5/2; Table 1), 39
were positive with all three mAbs, 18 positive for only microscopy. In selected cultures, TEM (Fig. 2 c, g) and
dot-immunoblot with Nb 8/0 confirmed the growth toNb 8/0 and Nb 5/2, 7 negative for all three, and 2 positive
only for chlamydial LPS. Thus, nearly all of the reactivity be nanobacteria. Growth media plus serum alone were
negative by dot-blot, light, and electron microscopy (Fig.of cyst fluids could be accounted for by nanobacterial
epitopes or cross reaction with mAb to chlamydial LPS; 2 a, e). Of the 13 filtered cyst fluids, 11 were nanobacteria
Fig. 1. Transmission electron micrographs
(TEM) and photomicrographs of human poly-
cystic kidney disease (PKD) kidney and or-
ganisms cultured from cyst fluids showing struc-
tures typical of Nanobacterium. (A) TEM of a
PKD kidney section from donor 14 (not stained
with uranyl acetate) showing electron-dense
structures of sizes typical of nanobacteria (80
to 500 nm) [23]. (B–D) TEM of kidney sections
stained with uranyl acetate showing nanobact-
eria (arrow; B; patient 1) with hairy apatite
layer surrounding a central cavity adjacent to
a tubule cell (C; patient 7; N, cell nucleus) and
with multiple apatite spicules in kidney cell
cytoplasm, and (D; patient 8) embedded in
basal lamina adjacent to tubule cell. (E) TEM
of pelleted kidney cyst fluid showing nanobac-
teria (arrows) surrounded by cellular debris
(patient 13). (F and G) IF micrographs of na-
nobacteria (arrows) cultured from kidney cyst
fluid from patients 7 (F; in suspension) and 8
(G; bound to surface of 3T6 cells), fixed, and
probed with Nb 8/0 followed by FITC-conju-
gated rabbit antimouse IgG. (H and I) IF mi-
crograph of Nb8/0-positive bacterium cultured
from patient 13 that has been internalized by
3T6 fibroblasts (H) and same field stained with
Hoechst 33258 (0.5 mg/mL) to visualize 3T6
cell nuclei (I) [26]. The absence of bacterial
staining in (I) indicates the absence of classic
bacteria that might have been carried along
during culture and testing; nanobacteria are
not stained by these conditions, but will stain
at 5 mg/mL and longer incubation times.
Fig. 1. (Continued).
Fig. 1. (Continued).
Hjelle et al: Endotoxin and nanobacteria in PKD 2367
Fig. 2. Nanobacteria (arrows) cultured from
PKD cyst fluids compared by light and elec-
tron microscopy with “Nanobacterium san-
guineum” after four weeks in vitro. (A and E )
Control RPMI-1640 with 10% Hg-irradiated
serum without nanobacteria. (B and F ) Media
plus N. sanguineum as reference culture (bar 5
20 m, A–D). (C and G) Media plus filtered
PKD kidney cyst fluid from donor 14. (D and
H ) Media plus unfiltered PKD cyst fluid (do-
nor 14) showing nanobacteria of diverse size.
The larger apatite structures (D and H) are
known to shelter the smaller coccoid forms of
nanobacteria [20].
Fig. 2. (Continued).
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Table 2. Assay of urines from control and PKD patients for tested against “Nanobacterium sanguineum” revealed
endotoxin and nanobacterial antigen
growth inhibition over the entire range of dilutions (0.05/
Dot immunoblota 0.06 to 28 mmol/L/33 mmol/L) tested.
Urine donor groups Nb 8/0 WN1 222.5 LAL assayb
PKD males 7/7; 3.1 7/7; 2.2 5/7; 1.24 EU/mL DISCUSSION
PKD females 1/7; 1.0 0/7 5/7; 1.36 EU/mL
Control males 3/10; 2.0 0/10 0/10 We have proposed that PKD is an emerging infectious
Control females 1/10; 1.0 4/10; 1.5 5/10; 0.26 EU/mL disease in a genetically vulnerable population [9]. To
aDot immunoblot results given as number positive of number tested; the establish the presence of nanobacteria in PKD kidneys,
scoring of HRP-reaction intensity is from 0 to 5. Positive reaction scores were
we used three criteria: nanobacterial morphology by EM,averaged. Nb 8/0 (nanobacterial porin protein epitope); WN1 222.5 (E. coli LPS
epitope) reactivity with mAb against nanobacteria, and growth
bClassic LAL assay detects the lipid A portion of endotoxin, but also reacts
(that is, multiplication) in culture [19–25]. Small size (80with fungal glucans [17]; positive findings averaged with estimates of EU/mL
based on serial dilutions to 500 nm) and calcification are two essential characteris-
tics of nanobacteria morphology. These criteria make a
compelling case for the presence of nanobacteria in
PKD. The immunologic cross reactivity of nanobacteriapositive when grown in serum-fortified media, and in
with two other known pathogens (Chlamydia and Barto-serum-free media only 6 showed growth by light micros-
nella) requires the use of multiple criteria to establishcopy. For nonfiltered cyst fluids cultured in serum-free
identity. Sequencing of novel nanobacterial proteins formedia, 10 of 15 were culture positive by light microscopy.
use as antigens may yield additional immunologic probesBy TEM and light microscopy, nanobacteria isolates
for nanobacteria in human specimens (Kajander, unpub-from donor 14 were indistinguishable from “Nanobacter-
lished data). Poor penetration of the calcium coat byium sanguineum” incubated in media with and without
DNA probes may limit a DNA-based approach to clini-serum for four weeks (Fig. 2 b, f).
cal specimens (Kajander, unpublished data).In two flasks of nonfiltered cyst fluid incubated in serum-
It is possible that humans are routinely exposed tofree media, nanobacteria were observed to be bound to
nanobacteria and clear them as a matter of normal physi-and present within PKD renal epithelial cells that were
ology. Five percent of 1000 Finnish volunteers exhibitedpresent in the aspirated cyst fluid (Fig. 3). By direct-
nanobacteremia [23]. In this United States-based study,phase microscopy, nanobacteria were observed to be
control males (30%) and females (10%) exhibited nano-actively endocytosed by the PKD cells in vitro (data
bacterial antigen in their urine (Table 2). In an unpub-not shown). The epithelial cells exhibited intracellular
lished work (Hjelle), 20 of 50 consecutive non-PKD hu-structures typical of highly mineralized forms of nano-
man kidney biopsies examined thoroughly by EM forbacteria (Fig. 3B) and other pleomorphic forms of nano-
nanobacteria showed structures compatible with nano-bacteria in vitro (Fig. 3C) [19, 20, 23]. Conditioned media
bacteria. Only patients with compromised kidney func-from this cell-containing culture of cyst fluid were posi-
tion (nondialyzed) were biopsied. As 60% of human kid-tive for endotoxin by the dLAL assay; both the filtered
ney biopsies did not show evidence of nanobacteria, theyand unfiltered cyst fluids grew nanobacteria.
might serve as a surrogate for control human kidneyUsing a 3T6-fibroblast test system, nanobacteria iso-
tissue. At this time, it is not known whether these findingslates from donors 1, 7, 8, 12, and 13 were screened for
represent episodic/continuous infections or colonizations.cytotoxicity. These isolates caused cytotoxicity that ranged
Theoretically, disease would occur if (1) nanobacteriafrom mild to severe (20 to 100% cell loss compared to
could not be cleared, (2) there was infection by virulentcontrol cultures) during the first 24 hours of exposure
species/strains of nanobacteria, or (3) genetic/environ-[26]. A loss of cells was estimated by microscopic inspec-
mental factors resulted in enhanced vulnerability to thistion. Within 15 minutes of exposure to 3T6 cells, nano-
microbe. All of these are possible in PKD.bacteria demonstrated binding to the cell surface (Fig.
Regarding these three general points, (1) the kidney1 F, G). When examined after 18 hours of incubation,
may play an important role in the clearance for this tiny,sequestration of IF signal within the 3T6 cells was appar-
calcium-coated cytotoxic organism. Akerman et al haveent (Fig. 1H).
reported that radiolabeled, viable nanobacteria appearedThe initial test of PKD-derived nanobacteria suscepti-
in urine within 15 minutes of their intravenous injectionbility to an antimicrobial agent used a serum-derived na-
into rabbits [27]. By TEM and silver staining, nanobact-nobacteria isolate from a 23-year-old Finnish PKD patient
eria were associated with the tubule epithelium and fluid.and tetracycline at 4 mg/mL, which completely inhibited
Nanobacteria were not observed in the control animals.growth (Fig. 4). In the absence of inhibitors, absorbance
Apoptosis of tubule cells at the site of nanobacterialincreased, indicating growth of nanobacteria typical of
localization was observed. Dysregulation of apoptosisa bacterial growth curve. Serial dilutions of potassium
citrate-citric acid (55 mmol/L/67 mmol/L) in DMEM and tubular obstruction are frequently observed in PKD
Fig. 3. Electron micrographs of PKD kidney
epithelial cells and nanobacteria present in
aspirated cyst fluid that was cultured five
weeks in vitro. (A) SEM revealed nanobact-
eria (arrows) bound to the plastic flask, accu-
mulated at the cell margin, and on the surface
of the cell (M, microvilli; white arrows). (B)
TEM shows highly mineralized form of nano-
bacteria (arrow) within the epithelial cell cyto-
plasm. (C) Also prominent were less mineral-
ized, somewhat lamellar structures containing
coccoid forms of nanobacteria (arrows) [20].
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a variety of animal sources [26]. The five random nano-
bacterial isolates from separate cystic kidneys (4 PKD,
1 simple cystic disease) tested in this study exhibited
cytotoxicity. The cytotoxic components of nanobacteria
are yet to be identified, but candidate toxins include its
putative chlamydia-like endotoxin reported here and its
mineral coat, which may contribute to free-radical for-
mation [39]. The LPS of Chlamydia pneumoniae is re-
ported to be a key component in its atherogenic effect
[40]. Endotoxin from at least two other genera of bacteria
was identified in cyst fluid. Thus, a portion of the renal
inflammation observed in PKD kidney [10] may be re-
lated to the presence of endotoxin, a potent inflamma-
tory agent and nephrotoxin.
Related and cross-reacting pathogens may share simi-
lar virulence factors and mechanisms of toxicity. Maurin
et al reported serological cross reactions between Barto-
nella and Chlamydia species for LPS and non-LPS epi-
topes [41]. We found hyperimmune sera to B. henselae,
a close phylogenetic relative of nanobacteria, reacted
with “Nanobacterium sanguineum” and cyst fluids from
all 12 PKD patients examined. Kajander et al observed
that Nb 5/2, but not Nb 8/0, reacted with intact Bartonella
[19]. Interestingly, patients with bacillary peliosis caused
by B. henselae develop cystic liver lesions [42]. Bartonella
sp. are also linked to cardiac and vascular lesions [43].
In PKD, cardiac and vascular lesions are a leading cause
of death, and liver cysts are found in 77% of patients by
age 60 [6]. The expression of Bartonella-induced pathol-
ogy is influenced by the patient’s immunocompetency
[43], a concept of potential relevance to PKD patients and
their reported heightened vulnerability to infection [14].Fig. 4. Effect of 4 mg/mL tetracycline (A) and potassium citrate/citrate
Our finding of reactivity of antichlamydial LPS withconcentration (B) on nanobacterial growth in vitro. (A) Growth of
nanobacteria isolated from PKD serum in the absence (open symbols) nanobacteria and cyst fluid suggests the presence of a
and presence (solid symbols) of drug (3 separate experiments). (B) chlamydia-like endotoxin. This raises the possibility thatGrowth of “Nanobacterium sanguineum” in the presence of increasing
certain routine immunologic tests may not distinguishK1 citrate/citrate levels: (d) zero, mean 6 SD, N 5 3; (h) 0.05/0.06
mmol/L; (m) 0.42/0.5 mmol/L; (s) 0.85/1.0 mmol/L; (r) 1.7/2.1 mmol/L; nanobacteria from Chlamydia sp. The nanobacteria-spe-
(n) 3.5/4.1 mmol/L; and (j) 7.0/8.2 mmol/L. Means, N 5 3, are shown cific mAb Nb 8/0 used in this study did not react withfor the citrate groups. Higher concentrations of citrate solution com-
intact C. pneumoniae (Kajander, unpublished observa-pletely inhibited growth (data not shown).
tions). C. pneumoniae has recently been implicated by
immunologic methods in the calcifying cardiovascular
disease observed in patients with renal failure [44], but
pathophysiology [28, 29, 31]. An inability to clear ob- C. pneumoniae has not been reported to cause tissue
structed tubules would lead to retention of nanobacteria, calcification. Carson has proposed that all extraskeletal
thereby providing selection pressure for the emergence calcifications are caused by nanobacteria, the only known
of more progressively cystic phenotypes [7, 8, 10, 11]. blood-born, calcium apatite-forming microbe [45].
Accumulation of nanobacteria caused by the lack of re- (3) Four points (a through d) relate to genetic/environ-
nal clearance would be consistent with their presence mental factors that impact PKD. (a) The distribution of
within poorly drained PKD cysts and simple kidney cysts PKD lesions in kidney, liver, vasculature, spleen, heart,
and the 80% rate of nanobacteremia in hemodialysis and colon follows the expression of polycystin 1, one of
patients [23]. Interestingly, 80% of non-PKD dialysis two proteins regarded as defective in PKD [11] and that
patients will develop acquired kidney cysts [6]. we have speculated may bind microbes or their compo-
(2) Pathogenic and nonpathogenic strains of nanobact- nents [9]. In this study, we found nanobacteria and/or
eria are possible given the range of cytotoxicities (no its antigens consistently in PKD kidneys, the available
multiple liver cysts from one patient and blood and urinetoxicity to 100% cell death) produced by isolates from
Hjelle et al: Endotoxin and nanobacteria in PKD2372
of another. While it is unknown whether nanobacteria currence and severity of kidney cysts, which are greater in
males, and liver cysts, which are greater in females [2, 6].bind to normal or PKD-defective polycystins, nanobac-
teria of PKD origin were found bound to and present These consistent, but as yet unexplained gender differ-
ences in expression of PKD pathology and pharmacologyin human PKD kidney cells in vivo and in vitro (Figs. 1
and 3) and rodent fibroblasts in vitro (Fig. 2). Cytotoxic- [49] are now reflected in the occurrence of nanobacterial
antigens in PKD urines (Table 2: PKD males . controlity was evident. Endocytosis of nanobacteria or its rem-
nants was required to induce apoptosis in fibroblasts [26], males . PKD females < control females). In contrast, the
endotoxin levels found in PKD individuals were greatera cell type that expresses polycystin 1 [11]. Calvet has
proposed that PKD involves a defect in cellular repair than those found in control females. Findings of both E.
coli LPS antigen and fivefold lower levels of Limulusmechanisms that would make PKD individuals especially
vulnerable to commonly encountered renotoxic environ- Amoebocyte Lysate positivity in control females may be
due simply to introital contamination (Table 2) [17].mental factors [11, 46].
(b) Kidney calcifications become several-fold more In summary, we demonstrate that cytotoxic nanobact-
eria are present in PKD patients. Based on our data,prevalent in PKD individuals than in the general popula-
tion [30]. Nanobacteria are now strongly linked to kidney we propose that the currently known cellular toxicities,
tissue distribution, and pharmacology of nanobacteriastone formation [24]. Hypocitraturia is a risk factor for
kidney stones [47]. The relationship between kidney calci- are plausibly related to the known pathology and phar-
macology of PKD. The mechanism responsible for thefication and cystogenesis is unclear. However, exogenous
citrate prevented loss of kidney function in genetically heightened vulnerability of PKD individuals to infection
and the lesions of PKD is unknown, but must ultimatelyPKD rats [38]. Dietary flaxseed meal, which increased
citrate levels in the kidney, also preserved kidney func- involve the loss of functional polycystins [10, 11]. Aware-
ness that nanobacteria are present in PKD, and likelytion in genetically PKD rats [48]. Based on our observa-
tion that citrate inhibits nanobacterial growth in vitro other kidney diseases and hemodialysis, may lead to
improved therapies and management. Additional re-(Fig. 4B), we propose that citrate protects against nano-
bacteria-driven stone formation in general and loss of search is required to prove that nanobacteria promote
PKD. Such infectious disease research will need carefulkidney function and reduced cyst volumes in PKD.
The mineral coat of nanobacteria may play a role in attention to the resistance of nanobacteria to most disin-
the concentration, persistence, and resultant killing action fectants and routine sterilizing techniques (that is, auto-
of tetracycline, a drug known to bind calcium and used in claving, radiation, filtration) [19, 22, 23], and the presence
the treatment of diseases with pathological calcifications. of nanobacteria in serum used for tissue culture [19, 20].
Putative C. pneumoniae infections have been treated with
tetracycline, a drug that also inhibited the growth in vitro
NOTE ADDED IN PROOFof PKD and animal isolates of nanobacteria (Fig. 4A).
A related review, Microbes in PKD, has recently beenCiftcioglu et al reported that tetracycline was bactericidal
published: Hjelle JT, Miller-Hjelle MA, Nowak DM,for nanobacteria at a minimum inhibitory concentration
Dombrink-Kurtzmun MA, Peterson SW: Polycysticof 0.3 mg/mL (abstract; Ciftcioglu et al, Gen Meet Am
kidney disease, fungi, and bacterial endotoxin: ShiftingSoc Microbiol 24, 1999). Tetracycline is considered bact-
paradigms involving infection and diet. Rev Med Micro-eristatic against other susceptible bacteria. Nanobacteria
biol 11:23–35, 2000.may have been the unintended target of therapies used
in a variety of chronic diseases with calciferous lesions.
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